With back­ing from Bay­er, a Lon­don firm will pitch its 'hos­pi­tals at home' con­cept for de­cen­tral­ized tri­als

Mon­ey is fly­ing for com­pa­nies promis­ing to rev­o­lu­tion­ize the way clin­i­cal tri­als are con­duct­ed. Leaps by Bay­er is the lat­est to get be­hind one of these play­ers, lead­ing a $200 mil­lion ven­ture round for Hu­ma Ther­a­peu­tics and its dig­i­tal “hos­pi­tal at home” tech.

Lon­don-based Hu­ma un­veiled a $130 mil­lion Se­ries C on Wednes­day, which it will use to ex­pand its dig­i­tal plat­form in the US, Asia and the Mid­dle East. As part of the round, the com­pa­ny can ex­er­cise an­oth­er $70 mil­lion com­mit­ment lat­er on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER